<?xml version="1.0" encoding="UTF-8"?>
<p id="p0440">At present, there is no evidence-based medicine to support the effectiveness of antiviral drugs for COVID-19. The previous experience of treating SARS-CoV, MERS-CoV or influenza infections guides the selection of antiviral agents for COVID-19. The current guideline of the NHC recommends IFN-α, lopinavir/ritonavir, and ribavirin as antiviral therapy. In Huang's study [
 <xref rid="bib26" ref-type="bibr">26</xref>], 38 of 41 patients were given antiviral therapy. The Jinyintan hospital has launched a randomized, controlled trial of the anti-HIV drug combination of lopinavir and ritonavir. In Chen's study [
 <xref rid="bib37" ref-type="bibr">37</xref>], 75 patients received antiviral treatment, including oseltamivir, ganciclovir, and lopinavir/ritonavir, and the duration of antiviral treatment was 3–14 days. In Wang's study [
 <xref rid="bib83" ref-type="bibr">83</xref>], there were 89.9% (124/138) patients who received oseltamivir. And in Guan's study, 35.8% (393/1099) of patients received oseltamivir [
 <xref rid="bib85" ref-type="bibr">85</xref>]. The anti-viral drug remdesivir (Gilead®) is in clinical trials to treat COVID-19 in Wuhan [
 <xref rid="bib132" ref-type="bibr">132</xref>]. Chloroquine phosphate has also been shown to be effective in some patients.
</p>
